22. Mai 2009
New Renal Pharma Website from Fresenius Medical Care – Interactive Online Training in Bone Metabolism
Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis services and products, has launched a new website focusing on dialysis medications ("renal pharmaceuticals"). At www.fmc-renalpharma.com, doctors as well as patients and the interested public are now able to find information about Fresenius Medical Care's pharmaceutical expertise.
The website provides information about the effectiveness of dialysis medication, proper treatment types, Fresenius Medical Care´s partners and the company itself. In addition, it includes a comprehensive glossary, a space for current news as well as a calendar of trade fairs and other events. The website also offers general information about dialysis medication and related areas of care, providing valuable information to non-specialist individuals. In-depth information about individual dialysis drugs is password protected due to the Medication Advertising Law and is only available to doctors and other medical personnel.
An additional feature of the Renal Pharma website is Dia-PhoCal (also available at www.diaphocal.com). This is an interactive training tool on bone mineral metabolism. Doctors and hospital employees can learn about the interaction between calcium, phosphate, parathormone (which regulates the calcium balance in the blood) and calcitriol (Vitamin D created by the kidneys) in dialysis patients and observe how these parameters in bone metabolism react to the introduction of various drugs. In adherence to Medication Advertising Law, Dia-PhoCal is also protected by a password.
Currently the site is available in English only. In future, further language versions as well as additional information about new products and especially information targeted to patients will be made available.
# # #
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,770,000 individuals worldwide. Through its network of 2,448 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 187,476 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).
Renal pharmaceuticals battle anemia and regulate the mineral bone metabolism of patients. The spectrum of dialysis drugs includes among others phosphate binders, Vitamin D and the calcimimetics group as well as iron supplements and Erythropoesis Stimulating Agents (ESA). Fresenius Medical Care currently offers the phosphate binders OsvaRen®, PhosLo® and Phosphosorb 660®, the potassium binder Sorbisterit® and the iron i.v. drug Venofer®.
For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.